- Home
- MHF vs AGEN Comparison
MHF vs AGEN Comparison
Compare MHF & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHF
- AGEN
- Stock Information
- Founded
- MHF 1988
- AGEN 1994
- Country
- MHF United States
- AGEN United States
- Employees
- MHF N/A
- AGEN N/A
- Industry
- MHF Finance/Investors Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MHF Finance
- AGEN Health Care
- Exchange
- MHF Nasdaq
- AGEN Nasdaq
- Market Cap
- MHF 153.3M
- AGEN 123.6M
- IPO Year
- MHF N/A
- AGEN 2000
- Fundamental
- Price
- MHF $7.22
- AGEN $4.19
- Analyst Decision
- MHF
- AGEN Buy
- Analyst Count
- MHF 0
- AGEN 2
- Target Price
- MHF N/A
- AGEN $14.50
- AVG Volume (30 Days)
- MHF 57.2K
- AGEN 471.8K
- Earning Date
- MHF 01-01-0001
- AGEN 11-11-2025
- Dividend Yield
- MHF 4.29%
- AGEN N/A
- EPS Growth
- MHF N/A
- AGEN N/A
- EPS
- MHF N/A
- AGEN N/A
- Revenue
- MHF N/A
- AGEN $101,706,000.00
- Revenue This Year
- MHF N/A
- AGEN $60.49
- Revenue Next Year
- MHF N/A
- AGEN N/A
- P/E Ratio
- MHF N/A
- AGEN N/A
- Revenue Growth
- MHF N/A
- AGEN N/A
- 52 Week Low
- MHF $5.92
- AGEN $1.38
- 52 Week High
- MHF $6.79
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- MHF 56.82
- AGEN 46.74
- Support Level
- MHF $7.00
- AGEN $3.96
- Resistance Level
- MHF $7.16
- AGEN $4.60
- Average True Range (ATR)
- MHF 0.10
- AGEN 0.24
- MACD
- MHF 0.01
- AGEN 0.03
- Stochastic Oscillator
- MHF 93.61
- AGEN 38.51
About MHF Western Asset Municipal High Income Fund Inc.
Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).